Youn H. Kim

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel et al. · Journal of Clinical Oncology · 2007 · 1K citations

Pharmacy, Oncology, Pharmacotherapy +16

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Sean Whittaker, Marie‐France Demierre, Ellen J. Kim et al. · Journal of Clinical Oncology · 2010 · 661 citations

Medicine, Oncology, Pharmacology +13

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Elise A. Olsen, Sean Whittaker, Youn H. Kim et al. · Journal of Clinical Oncology · 2011 · 658 citations · Full text

Medicine, Dermatology, Oncology +17

Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome

Youn H. Kim, Howard L. Liu, Serena Mraz‐Gernhard et al. · Archives of Dermatology · 2003 · 652 citations

Medicine, Dermatology, Oncology +16

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13